Comparison 3. Tivozanib versus Sorafenib.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 Progression‐free survival	1		Hazard Ratio (IV, Random, 95% CI)	Totals not selected
3.2 Overall survival	1		Hazard Ratio (IV, Random, 95% CI)	Totals not selected
3.3 Serious adverse events (Grade 3 or 4)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.4 Health‐related quality of life	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
3.5 Response rate	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.6 Minor adverse events (Grade 1 or 2)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected